Dr. Efstathiou asks Dr. Freedland:Let's start by discussing the importance of early intervention in castration-sensitive prostate cancer (CSPC). What are the potential benefits of treating patients earlier in their disease course?
How does early intervention impact long-term outcomes and quality of life?
What are the risks of delaying systematic treatment?
Dr. Freedland asks Dr. Efstathiou: Discuss the significance of biomarker and genetic testing, as well as imaging, in diagnosis of patients with prostate cancer.
David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.